ARPO Aerpio Pharmaceuticals Inc

Nigeria's Antigraft Agency, The Economic and Financial Crimes Commission (EFCC), removes Benedict Peters From 'Wanted' List

Aiteo Group
Nigeria's Antigraft Agency, The Economic and Financial Crimes Commission (EFCC), removes Benedict Peters From 'Wanted' List

06-Nov-2018 / 19:00 CET/CEST


NIGERIA'S ANTIGRAFT AGENCY, EFCC, REMOVES BENEDICT PETERS FROM 'WANTED' LIST

The Economic and Financial Crimes Commission (EFCC), has conformed with the order of Nigeria's High Court, directing the removal of the name of the Executive Vice Chairman of Aiteo Group, Benedict Peters, from its list of wanted persons. This action confirms EFCC's compliance with the judgment handed down in March 2018, by Justice O.A. Musa of the High Court of the Federal Capital Territory. Justice Musa had ordered that Peters' name be taken down from the anti-graft agency's website, describing the process leading to his declaration as 'wanted' by EFCC as unconstitutional, since it was not initiated or validated by any known law or court order.

Reacting to this development, renowned Constitutional and Human Rights Lawyer, Chief Mike Ozekhome, SAN, said: "We wish to commend the Economic and Financial Crimes Commission (EFCC), under the leadership of Ibrahim Magu, for living up to its commitment to uphold the rule of law and obey the order of a competent court to remove the name of the Mr. Benedict Peters, from its list of wanted individuals. The EFCC has shown a deep regard for the sanctity of the nation's legal system, and we can confirm that Peters' name has been cleared. In view of this and based on the fact that the decision by EFCC is premised on a court order, Peters has been legally excluded from the list of wanted persons in Nigeria. He can therefore continue his lawful business and enjoy his constitutionally guaranteed rights."

The EFCC in March 2017 declared Peters wanted on its website. However, in response to suit, FCT/HC/CV/23/2017, the court reached the incontrovertible conclusion that Peters has never been charged with, nor tried for any criminal offence in any court of law, nor has he ever jumped bail for any offence howsoever in Nigeria and cannot be declared wanted by administrative fiat without any prior order or leave of court. In the proceedings challenging EFCC's actions, Justice Musa declared that ".the very act of declaring the Applicant (Benedict Peters) a WANTED PERSON on the official website of the 1st Respondent (EFCC) without any prior order or leave of a Court of competent jurisdiction to that effect is unlawful, illegal, wrongful, ultra vires, unconstitutional and constitutes a flagrant violation of the Fundamental rights of the Applicant to personal liberty, private and family life, freedom of movement and Right to not to be subjected to inhuman treatment and degrading treatment as guaranteed under Section 34, 37, 41 and 46 of the constitution of the Federal Republic of Nigeria, 1999 (As amended) and Articles 2, 3(1) & (2), 4, 5, 6, 7, and 12(1) of the African Charter on Human and Peoples' Rights (Ratification and Enforcement) Act 2004".

Benedict Peters has recorded successful outcomes in three other cases, including one overturning the forfeiture of his properties which were wrongfully included in a list of properties belonging allegedly belonging to a former minister forfeited by court orders.

Signed,
Andrew Onyearu
General Counsel
Aiteo Group.



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

742237  06-Nov-2018 

fncls.ssp?fn=show_t_gif&application_id=742237&application_name=news&site_id=research_pool
EN
06/11/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aerpio Pharmaceuticals Inc

 PRESS RELEASE

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes LOS ANGELES, June 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced it will join both the U.S. small cap Russell 2000® Index and broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective immediately after the U.S. market opens on June 24, 2022 according to a preliminary list of add...

 PRESS RELEASE

Aadi Bioscience to Present at the Jefferies Global Healthcare Conferen...

Aadi Bioscience to Present at the Jefferies Global Healthcare Conference LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022. Founder, Chief Executive Officer and President, Neil Desai, Ph.D. is scheduled to present live during a fire...

 PRESS RELEASE

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor R...

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications. “We are delighted to welcome Marcy to the team, as she brings extensive experience to ...

 PRESS RELEASE

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in ...

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor exposure LOS ANGELES, May 26, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced presentat...

 PRESS RELEASE

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Co...

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi’s executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Mia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch